Eloquest Healthcare and Vancive Medical Technologies Launch Antimicrobial Post-Operative Dressings
August 08 2017 - 9:00AM
Business Wire
The FDA-cleared dressings are now
commercially available in the United States
Vancive Medical Technologies™, an Avery Dennison (NYSE:AVY)
business, and Eloquest Healthcare®, Inc. have partnered to develop
an innovative post-operative dressing that contains an
antimicrobial agent called chlorhexidine gluconate (CHG). The
antimicrobial properties of CHG inhibit microbial growth within the
dressing.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170808005550/en/
CHG is extremely difficult to incorporate in an absorbent
adhesive dressing, making the development of the BeneHold™ CHG
platform a significant technical accomplishment for Vancive. The
Eloquest Healthcare ReliaTect™ Post-Op Dressings with CHG are the
first to combine CHG in an absorbent, transparent and waterproof
design.
“ReliaTect post-operative dressings are a natural fit for our
BeneHold CHG platform, and the needs of patients and clinicians,”
said Kirsten Newquist, general manager for Vancive Medical
Technologies. “We look forward to further expanding our CHG
technology to many more applications.”
ReliaTect is available in small and large sizes with a
transparent window for surgical site visualization, and a nonwoven
border that facilitates dressing application and provides
additional securement during wear. The dressings comfortably adhere
to the skin, absorb fluids and protect the site from external
contaminants.
“Chlorhexidine Gluconate (CHG) is a trusted antiseptic in
pre-operative site treatment,” said Tim O’Halla, president and CEO
for Eloquest Healthcare. “By combining its antimicrobial properties
with the sustained transparency and absorbency of our ReliaTect
Post-Op Dressings, we are bringing to market a truly patient
friendly post-operative dressing with proven antimicrobial
activity.”
ReliaTect Post-Op Dressings with CHG are now commercially
available from Eloquest Healthcare in the United States. The device
received 510(k) clearance from the FDA in March and is now
available nationwide. Eloquest Healthcare is the exclusive
distributor of the dressings in the United States and Canada.
To learn more or request a sample visit, www.ReliaTectPostOp.com
or contact Eloquest Healthcare customer service at
1-877-433-7626.
About Eloquest Healthcare
Eloquest Healthcare, Inc. is a wholly owned subsidiary of
Ferndale Pharma Group, Inc. that is focused specifically on serving
hospitals, their healthcare practitioners, and patients. Eloquest
Healthcare helps deliver safer, more compassionate care by
providing intuitive, cost-effective solutions that complement
treatment protocols. More information can be found at
www.eloquesthealthcare.com.
About Vancive Medical Technologies
Vancive Medical Technologies is a medical technology company
with more than three decades of expertise in adhesive chemistries
and material technologies for medical applications using pressure
sensitive adhesives. The company's applications and technologies
are an integral part of products that are in daily use in medical
facilities throughout the world. Through long-term relationships
with original equipment manufacturers, industry-specific converters
and leading universities, Vancive Medical Technologies continually
finds new ways to develop products that can improve patient care.
Vancive Medical Technologies is an Avery Dennison business
headquartered in Chicago, Illinois. To learn more about Vancive
Medical Technologies, visit www.vancive.averydennison.com.
About Avery Dennison
Avery Dennison (NYSE:AVY) is a global leader in
pressure-sensitive and functional materials and labeling solutions
for the retail apparel market. The company’s applications and
technologies are an integral part of products used in every major
industry. With operations in more than 50 countries and more than
25,000 employees worldwide, Avery Dennison serves customers in the
consumer packaging, graphical display, logistics, apparel,
industrial and healthcare industries. Headquartered in Glendale,
California, the company reported sales of $6.1 billion in 2016.
Learn more at www.averydennison.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170808005550/en/
Eloquest Healthcare Contact:Matthew StahlClinical Marketing
& Brand
Director248.586.8428mstahl@eloquesthealthcare.comorVancive
Contacts:Andrew DeckertGlobal Marketing Communications Manager+1
224 374 2109andrew.deckert@averydennison.comorBarbara Van
RymenamGlobal Director, CHG Program+32 (0)497
103233barbara.van.rymenam@eu.averydennison.com
Avery Dennison (NYSE:AVY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avery Dennison (NYSE:AVY)
Historical Stock Chart
From Apr 2023 to Apr 2024